Immunometabolism and mitochondria in inflammatory bowel disease: a role for therapeutic intervention?

Inflammatory bowel diseases (IBDs), incurable conditions characterised by recurrent episodes of immune-mediated gut inflammation and damage of unknown aetiology, are common. Current advanced therapies target key leukocyte-trafficking and cytokine-signalling hubs but are only effective in 50% of pati...

Full description

Saved in:
Bibliographic Details
Published inDisease models & mechanisms Vol. 17; no. 10
Main Authors Adams, Claire E, Rutherford, Duncan G, Jones, Gareth R, Ho, Gwo-Tzer
Format Journal Article
LanguageEnglish
Published England The Company of Biologists Ltd 01.10.2024
Subjects
Animals
Humans
Inflammatory Bowel Diseases - immunology
Inflammatory Bowel Diseases - metabolism
Inflammatory Bowel Diseases - pathology
Mitochondria - metabolism
Online AccessGet full text

Cover

More Information
Summary:Inflammatory bowel diseases (IBDs), incurable conditions characterised by recurrent episodes of immune-mediated gut inflammation and damage of unknown aetiology, are common. Current advanced therapies target key leukocyte-trafficking and cytokine-signalling hubs but are only effective in 50% of patients. With growing evidence of mitochondrial dysfunction in IBD and advances in our understanding of the role of metabolism in inflammation, we provide an overview of novel metabolic approaches to IBD therapy, challenging the current 'therapeutic ceiling', identifying critical pathways for intervention and re-imagining metabolic biomarkers for the 21st century.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
The authors declare no competing or financial interests.
Competing interests
ISSN:1754-8403
1754-8411
1754-8411
DOI:10.1242/dmm.050895